With the global tightening of pharmaceutical safety regulations and the rising focus on public health, abandoning ethylene oxide (EO) sterilization has become an irreversible trend in the hollow capsule industry. This transformation not only reshapes the production model, quality control system and competitive landscape of the industry but also paves the way for technological innovation and sustainable development. This report deeply analyzes the multi-dimensional impacts of EO-free sterilization and explores its future development directions, providing insights for industry participants to adapt to changes and seize opportunities.
1. Impacts of Ethylene Oxide-Free Sterilization on Hollow Capsule Production
1.1 Positive Impacts: Elevating Safety, Compliance and Brand Value
Product Safety Upgrade: EO, a toxic and potentially carcinogenic chemical, has long posed risks of residual contamination in hollow capsules. Eliminating EO sterilization fundamentally avoids such risks, ensuring that capsule products meet the strict residual limits specified in the 2025 Chinese Pharmacopoeia (≤1μg/g) and international standards such as the European Pharmacopoeia (Ph. Eur.) and United States Pharmacopoeia (USP). This is particularly critical for capsules used in pharmaceuticals and health products, as it directly safeguards drug efficacy and patient safety, reducing the risk of adverse reactions caused by chemical residues.
Enhanced Regulatory Compliance: The release of the T/CNPPA "General Requirements for Hollow Capsules" in China, which prohibits EO terminal sterilization in principle, and the tightened policies of the European Medicines Agency (EMA) and U.S. Environmental Protection Agency (EPA) have raised the industry's compliance threshold. Enterprises adopting EO-free processes can proactively meet regulatory requirements, avoid penalties such as import restrictions, product destruction and enhanced inspection rates, and gain smooth access to global markets. For example, leading enterprises like ACG Group have secured market access advantages in North America and Asia by building EO-free production bases.
Brand Competitiveness Enhancement: In the context of escalating consumer demand for safe and green products, EO-free has become a core competitive label for hollow capsule enterprises. Products manufactured without EO sterilization are more favored by downstream pharmaceutical and health product companies, especially those targeting high-end markets and export-oriented businesses. This helps enterprises establish a high-quality brand image, strengthen cooperation with core customers, and gain a premium in market pricing. Data shows that EO-free hollow capsules command a 15%-20% price premium in the international market compared to conventional products .
1.2 Practical Challenges: Cost, Technology and Supply Chain Adaptation
Increased Initial Investment and Operational Costs: Transitioning to EO-free processes requires substantial upfront investment in equipment upgrading and workshop renovation. For instance, building a Grade A cleanroom (the highest standard for pharmaceutical production environments) and installing intelligent monitoring systems such as "black boxes" can increase initial investment by 30%-50% compared to traditional production lines . Additionally, adopting alternative technologies like electron beam irradiation or dual reverse osmosis + EDI purified water systems leads to higher operational costs, including energy consumption, equipment maintenance and professional personnel training. This poses significant financial pressure on small and medium-sized enterprises (SMEs) with limited capital strength.
High Technical Threshold and Process Risks: EO-free production relies heavily on total-process aseptic control, which demands rigorous management of personnel, equipment, materials, methods and environment. Unlike EO sterilization which can compensate for process deficiencies through terminal treatment, any loophole in the production process may lead to microbial contamination. Enterprises need to master core technologies such as raw material microbial control, cleanroom environment regulation and real-time data monitoring, and establish a complete process verification system. For SMEs lacking technical accumulation, this transformation faces high technical risks and a long adaptation cycle.
Supply Chain Reconstruction Pressure: The popularization of EO-free processes drives upstream and downstream supply chain adjustments. Raw material suppliers must meet stricter microbial limits (even higher than national standards) to align with downstream production requirements; logistics and storage enterprises need to upgrade cold chain and clean storage conditions to maintain product sterility. This requires the entire industry chain to establish a coordinated quality control system, and enterprises that fail to adapt to this change may be eliminated from the supply chain. It is predicted that 20%-30% of SMEs in China will face elimination or integration due to inability to complete EO-free transformation by 2027 .
2. Future Development Trends of Ethylene Oxide-Free Hollow Capsule Production
2.1 Technological Innovation: Diversification and Maturity of Alternative Solutions
Total-Process Aseptic Control as the Mainstream: With continuous optimization of production processes and advancement of intelligent technology, total-process aseptic control will become the standard production model for the industry. Enterprises will further strengthen microbial control in every link, such as adopting automated raw material pretreatment systems, real-time online microbial detection technology and AI-based cleanroom environment regulation. By 2030, the coverage rate of fully automated aseptic production lines in the global hollow capsule industry is expected to exceed 60%, and unit energy consumption will decrease by 20%-30% compared to 2025 .
Continuous Advancement of Alternative Sterilization Technologies: Physical sterilization technologies will be further upgraded and popularized. Electron beam irradiation sterilization will become more widely used due to its high efficiency, no residue and short processing time, and the construction of professional irradiation platforms in industrial parks will reduce the cost of using this technology for enterprises. Meanwhile, low-temperature plasma sterilization with hydrogen peroxide and chlorine dioxide gas sterilization will be optimized for application in thermosensitive capsule materials, gradually solving the problem of material performance damage caused by traditional physical sterilization . R&D of green chemical sterilization technologies will also accelerate, aiming to develop low-toxicity, degradable and residue-free sterilants.
Innovation of New Materials Promoting Process Optimization: Plant-based materials represented by hydroxypropyl methylcellulose (HPMC) will gain faster market penetration, with their market share expected to exceed 35% by 2030 . Compared with animal-derived gelatin, plant-based materials have better microbial stability, reducing the difficulty of aseptic production. Additionally, R&D of biodegradable materials such as starch-based and polysaccharide-based capsules will advance, and industrialized production is expected to be realized around 2028, further aligning EO-free production with environmental protection trends .
2.2 Industry Pattern: Concentration Improvement and Global Layout Adjustment
Intensified Industry Integration and Concentration Upgrade: The high cost and technical threshold of EO-free transformation will accelerate the survival of the fittest in the industry. Leading enterprises with capital, technology and scale advantages will expand through mergers and acquisitions of SMEs, and the market share will further concentrate. It is predicted that by 2030, 3-5 leading enterprises with annual sales exceeding 3 billion yuan will emerge in China, accounting for over 70% of the high-end market share . SMEs will need to focus on niche markets such as customized capsules for children's drugs or functional health products to gain a foothold.